Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
Author: Jiang, HY
Pierce, GF
Ozelo, MC
de Paula, EV
Vargas, JA
Smith, P
Summer, J
Luk, A
Manno, CS
High, KA
Arruda, VR
Abstract: In a phase I study, administration of an AAV2-FIX vector into the skeletal muscle of eight hemophilia B subjects proved safe and achieved local gene transfer and FIX expression for at least 10 months after vector injection, the last time point assessed by muscle biopsy. In hemophilia B dogs we have demonstrated FIX in both muscle biopsies and circulation >4 years following AAV2-FIX injection. Because circulating FIX levels remained less than 1% of normal in human subjects from the study, the duration of AAV2-mediated transgene expression in humans is unknown. We sought to determine if FIX gene transfer and expression persisted locally at injection sites. Muscle biopsies were obtained from one subject 3.7 years following treatment and revealed transgene FIX DNA and protein by quantitative PCR, DNA fluorescence in situ hybridization, and immunohistochemistry for FIX. These results demonstrate, for the first time, multiyear FIX expression by AAV2 vector in humans and suggest that improved muscle delivery provides effective treatment for protein deficiencies or muscle-specific diseases.
Subject: adeno-associated virus
gene therapy
skeletal muscle
Country: EUA
Editor: Academic Press Inc Elsevier Science
Citation: Molecular Therapy. Academic Press Inc Elsevier Science, v. 14, n. 3, n. 452, n. 455, 2006.
Rights: fechado
Identifier DOI: 10.1016/j.ymthe.2006.05.004
Date Issue: 2006
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000240441500019.pdf241.99 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.